Analysts Set Haleon plc (NYSE:HLN) Price Target at $10.95

Shares of Haleon plc (NYSE:HLN) have earned an average rating of “Hold” from the eight research firms that are currently covering the company, MarketBeat reports. Six analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $10.95.

Several equities analysts recently issued reports on HLN shares. HSBC reiterated a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Hsbc Global Res cut Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a research report on Monday, March 3rd.

Institutional Trading of Haleon

Several institutional investors have recently bought and sold shares of the company. Sierra Ocean LLC purchased a new stake in shares of Haleon during the fourth quarter valued at approximately $26,000. Versant Capital Management Inc boosted its stake in Haleon by 2,029.1% during the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock valued at $34,000 after purchasing an additional 3,348 shares during the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Haleon in the 4th quarter worth $35,000. Toronto Dominion Bank raised its stake in shares of Haleon by 3,470.0% in the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after purchasing an additional 3,470 shares during the last quarter. Finally, Spire Wealth Management bought a new position in shares of Haleon during the fourth quarter valued at $39,000. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Price Performance

Shares of HLN stock opened at $10.28 on Thursday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon has a fifty-two week low of $7.99 and a fifty-two week high of $10.80. The firm has a market cap of $46.52 billion, a P/E ratio of 30.22, a P/E/G ratio of 2.82 and a beta of 0.25. The business’s 50 day moving average price is $9.96 and its 200-day moving average price is $9.87.

Haleon (NYSE:HLN) last released its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The business had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.38 billion. On average, equities research analysts anticipate that Haleon will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The business also recently announced a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be issued a $0.1166 dividend. This represents a yield of 1.6%. This is an increase from Haleon’s previous — dividend of $0.05. The ex-dividend date of this dividend is Friday, April 25th. Haleon’s payout ratio is 58.97%.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.